Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand. It also provides Divina 3D surgical simulation systems to plastic surgeons for use in pre-surgical patient consultations and planning; and Motiva Flora Tissue Expander, a breast tissue expander, as well as distributes Puregraft line of products for autologous adipose tissue harvesting and redistribution. The company sells its products through exclusive distributors and direct sales force in Europe, Latin America, the Asia-Pacific, and internationally. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.
IPO Year: 2018
Exchange: NASDAQ
Website: establishmentlabs.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/22/2024 | $60.00 | Buy → Neutral | Citigroup |
| 8/31/2023 | $75.00 | Overweight | JP Morgan |
| 6/29/2023 | $79.00 | Buy | Citigroup |
| 10/14/2022 | $90.00 | Overweight | Stephens |
| 10/13/2022 | $70.00 | Buy | Mizuho |
| 8/24/2022 | $107.00 | Buy | B. Riley Securities |
| 11/10/2021 | $88.00 → $90.00 | Overweight | Stephens & Co. |
| 8/3/2021 | $68.00 → $78.00 | Neutral | Goldman Sachs |
| 6/23/2021 | $82.00 → $88.00 | Buy | BTIG |
SCHEDULE 13G/A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)
10-Q - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)
8-K - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)
424B5 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)
8-K - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)
8-K - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)
8-K - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)
8-K - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)
10-Q - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)
8-K - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)
4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
3 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
- SEC Filing
Citigroup analyst Joanne Wuensch maintains Establishment Labs Hldgs (NASDAQ:ESTA) with a Neutral and lowers the price target from $60 to $50.
Mizuho analyst Anthony Petrone maintains Establishment Labs Hldgs (NASDAQ:ESTA) with a Buy and raises the price target from $65 to $70.
The inspection by the FDA has been rescheduled from the previously confirmed dates to take place within the next thirty days.
5 analysts have expressed a variety of opinions on Establishment Labs Hldgs (NASDAQ:ESTA) over the past quarter, offering a diverse set of opinions from bullish to bearish. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 1 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 0 0 0 2M Ago 2 0 0 0 0 3M Ago 0 2 0 0 0 The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $59.6, a high estimate of $65.00, and a low estimate of $53.00. This current aver
Citigroup analyst Joanne Wuensch downgrades Establishment Labs Hldgs (NASDAQ:ESTA) from Buy to Neutral and maintains the price target from $60 to $60.
Establishment Labs Hldgs (NASDAQ:ESTA) reported quarterly losses of $(0.58) per share which beat the analyst consensus estimate of $(0.67) by 13.43 percent. The company reported quarterly sales of $37.200 million which beat the analyst consensus estimate of $36.001 million by 3.33 percent. This is a 20.04 percent decrease over sales of $46.524 million the same period last year.
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. Here's the list of options activity happening in today's session: Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume MRK CALL SWEEP BEARISH 06/21/24 $130.00 $1.9 million 3.8K 15.0K PFE CALL SWEEP BEARISH 05/17/24 $28.0
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, noted the presentation today of an update on the Motiva US IDE Study. The update will include four-year patient follow-up data for primary augmentation subjects. The Medical Director of the Study, Dr. Caroline Glicksman, who is also an Investigator in the Study, will present the results at The Aesthetic Meeting 2024 in Vancouver, BC Canada.Dr. Glicksman will present data for the 451 primary augmentation patients enrolled in the study through the four-year follow-up visit. Patient compliance in the primary
4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)
SC 13G - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)
SC 13G - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)
SC 13G/A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)
SC 13G/A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)
SC 13G - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)
SC 13G/A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)
SC 13G/A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)
SC 13G/A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)
SC 13G/A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)
SC 13G/A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)
Citigroup downgraded Establishment Labs from Buy to Neutral and set a new price target of $60.00
JP Morgan initiated coverage of Establishment Labs with a rating of Overweight and set a new price target of $75.00
Citigroup initiated coverage of Establishment Labs with a rating of Buy and set a new price target of $79.00
Stephens resumed coverage of Establishment Labs with a rating of Overweight and set a new price target of $90.00
Mizuho initiated coverage of Establishment Labs with a rating of Buy and set a new price target of $70.00
B. Riley Securities initiated coverage of Establishment Labs with a rating of Buy and set a new price target of $107.00
Stephens & Co. reiterated coverage of Establishment Labs Hldgs with a rating of Overweight and set a new price target of $90.00 from $88.00 previously
Goldman Sachs reiterated coverage of Establishment Labs Hldgs with a rating of Neutral and set a new price target of $78.00 from $68.00 previously
BTIG reiterated coverage of Establishment Labs Hldgs with a rating of Buy and set a new price target of $88.00 from $82.00 previously
Cowen reiterated coverage of Establishment Labs with a rating of Outperform and set a new price target of $80.00 from $60.00 previously
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced today that Jeff Ehrhardt has joined the company as General Manager of North America. After having spent over 25 years at Allergan Aesthetics, an Abbvie Company, Mr. Ehrhardt joins Establishment Labs with responsibilities including the anticipated launch of Motiva implants in the U.S. later this year. "Jeff is the ideal person to introduce Motiva to the United States," said Juan José Chacón-Quirós, CEO and Founder of Establishment Labs. "Just as we have changed the standard for breast augmentat
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced the appointment of Raj Denhoy as Chief Financial Officer effective immediately. Mr. Denhoy has been with the company since February 2021, including as Interim Chief Financial Officer since August. "Raj has quickly become a trusted and vital colleague to me and many others at Establishment Labs," said Juan José Chacón-Quirós, Founder and CEO of Establishment Labs. "His depth of knowledge about our business and industry are matched by a clear vision of what we must do to achieve success as
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced the appointment of Leslie Gillin to its Board of Directors, effective immediately. "We are very pleased to welcome Leslie to the Board of Establishment Labs," said Juan José Chacón-Quirós, Founder and CEO of Establishment Labs. "She is extraordinarily accomplished in consumer marketing and finance, and her experience and insights will be invaluable as we continue to transform our industry by engaging directly with patients and by advancing new business and payment models." "I couldn't be
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a medical technology company focused on women's health, initially in the breast aesthetics and reconstruction market, today announced the appointment of Ann Custin and Bryan Slotkin to its Board of Directors, effective immediately. "We are delighted to have these two very accomplished individuals join the Board of Establishment Labs," said Juan José Chacón-Quirós, Founder and CEO of Establishment Labs. "Good governance is essential to our mission of improving women's health. Their unique perspectives will be critical as we continue to reshape and expand our industry by offering differentiated technologies that create value for all stakeholder
Company also announces preliminary second quarter 2021 revenue of $31 million to $32 million Establishment Labs Holdings Inc. (NASDAQ:ESTA), a medical technology company focused on women's health, initially in the breast aesthetics and reconstruction market, today announced that Renee Gaeta will step down from her position as Chief Financial Officer for another opportunity outside of the company, effective July 30, 2021 and following the planned release of the company's second quarter financial results. Raj Denhoy, Head of Strategy and Investor Relations, has been named Interim Chief Financial Officer effective upon Mrs. Gaeta's departure. Establishment Labs also announced that prelimin
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a medical technology company focused on women's health, initially in the breast aesthetics and reconstruction market, announced today that Pratip Dastidar has been appointed Head of Global Operations. Mr. Dastidar will join the executive team at Establishment Labs with responsibility for operational transformation and the scaling of global operations; he will also lead the company's digital transformation initiatives. Mr. Dastidar joins Establishment Labs from ServiceMaster, where he served as Chief Transformation Officer from 2018 to 2020. He previously was Head of Process Innovation at Salesforce and has held executive roles at Hewlett Pack
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in three upcoming investment conferences. Juan José Chacón-Quirós, Chief Executive Officer and Founder, and Raj Denhoy, Chief Financial Officer, will participate in the 2024 UBS Global Healthcare Conference being held November 11-14, 2024. Mr. Chacón-Quirós and Mr. Denhoy are scheduled to speak to conference attendees on Tuesday, November 12 at 2:00-2:35 PM PST. Mr. Chacón-Quirós will participate in the 2024 Jefferies London Healthcare Conference held November 19-21,
Establishment Labs Holdings Inc. (NASDAQ:ESTA) (the "Company"), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced that it has entered into a securities purchase agreement (the "Purchase Agreement") with select purchasers for the purchase of 765,696 common shares and pre-funded warrants to purchase up to 328,161 common shares in a registered direct offering for aggregate gross proceeds of approximately $50 million. The purchase price for the common shares is $45.71 per share and the purchase price for the pre-funded warrants is $45.709 per warrant, which represents the per share purcha
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the third quarter ended September 30, 2024. Third Quarter Highlights and Outlook Third quarter worldwide revenue of $40.2 million. 2024 revenue guidance updated to $165 million to $168 million from previous guidance of $174 million to $184 million. Third quarter loss from operations was $13.1 million compared to a loss of $21.0 million in the year-ago period. Adjusted EBITDA loss of $7.0 million compared to a loss of $16.3 million in the year-ago period. Th
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced the presentation of three-year clinical results with Mia Femtech™ at the 9th Annual World Symposium on Ergonomic Implants (WSEI) being held this week in Barcelona, Spain. The Mia Femtech Clinical Study is an IRB-approved prospective study that enrolled 100 subjects between December 2020 and April 2021. In the preliminary three-year analysis of key complications, there were no reports of capsular contracture (Baker Grade III/IV) and no ruptures (suspected or confirmed). There were also no report
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended September 30, 2024, after the market closes on Thursday, November 7, 2024, and will host a conference call at 4:30 pm ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U.S. and Canada) or (201) 689-8037 (International) and use conference ID number 13749629. The call will also be available via live or archived webcast on the "Investor Relations" section of the Establishment Labs website at www.est
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced that it has published its 2024 Post Market Surveillance (PMS) Report. "It is fitting that as we publish our 2024 PMS report, we begin broadly shipping across the United States," said Juan José Chacón-Quirós, Establishment Labs CEO and Founder. "Dozens of plastic surgeons will perform their first Motiva surgery in the coming days, and they are actively talking about the advantages of Motiva Implants on social media. Many women are responding, accepting only Motiva Implants for their surgery. Not
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced today that the first patients in the United States have successfully undergone breast augmentation with Motiva® Implants. "With the FDA approval last week, we are experiencing high demand for Motiva Implants — both from surgeons and patients," said Juan José Chacón-Quirós, Founder and Chief Executive Officer of Establishment Labs. "The FDA approval came as we were attending the annual conference of the American Society of Plastic Surgeons. The response was overwhelming, and our team has already
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced it has received approval from the U.S. Food and Drug Administration (FDA) for the use of Motiva® SmoothSilk® Ergonomix® and Motiva® SmoothSilk® Round breast implants in primary and revision breast augmentation. "Today's approval is transformative for breast aesthetics in the United States. This is a new era, in which women now have a choice of highly differentiated technology that is backed by rigorous scientific and clinical research," commented Juan José Chacón-Quirós, Founder and Chief Execu
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the second quarter ended June 30, 2024. Second Quarter Highlights and Outlook Second quarter worldwide revenue of $44.1 million. 2024 revenue guidance remains $174 million to $184 million, an increase of 5% to 11% over 2023. Gross profit for the second quarter was $28.9 million, or 65.6% of revenue, compared to $30.3 million, or 62.3% of revenue in the year-ago period. Second quarter loss from operations was $9.3 million compared to a loss of $13.7 milli
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended June 30, 2024, after the market closes on Tuesday, August 6, 2024, and will host a conference call at 4:30 pm ET that day to discuss those results. To participate in the conference call, dial (800) 715-9871 (U.S. and Canada) or (646) 307-1963 (International) and use conference ID number 7160745. The call will also be available via live or archived webcast on the "Investor Relations" section of the Establishment Labs website at www.establishme
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended September 30, 2024, after the market closes on Thursday, November 7, 2024, and will host a conference call at 4:30 pm ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U.S. and Canada) or (201) 689-8037 (International) and use conference ID number 13749629. The call will also be available via live or archived webcast on the "Investor Relations" section of the Establishment Labs website at www.est
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the second quarter ended June 30, 2024. Second Quarter Highlights and Outlook Second quarter worldwide revenue of $44.1 million. 2024 revenue guidance remains $174 million to $184 million, an increase of 5% to 11% over 2023. Gross profit for the second quarter was $28.9 million, or 65.6% of revenue, compared to $30.3 million, or 62.3% of revenue in the year-ago period. Second quarter loss from operations was $9.3 million compared to a loss of $13.7 milli
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended June 30, 2024, after the market closes on Tuesday, August 6, 2024, and will host a conference call at 4:30 pm ET that day to discuss those results. To participate in the conference call, dial (800) 715-9871 (U.S. and Canada) or (646) 307-1963 (International) and use conference ID number 7160745. The call will also be available via live or archived webcast on the "Investor Relations" section of the Establishment Labs website at www.establishme
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the first quarter ended March 31, 2024. First Quarter Highlights and Outlook First quarter worldwide revenue of $37.2 million. 2024 revenue guidance remains $174 million to $184 million, an increase of 5% to 11% over 2023. Guidance does not include revenue from Motiva Implants® in the United States, which is expected in 2024. Gross profit for the first quarter was $24.4 million, or 65.6% of revenue, compared to $30.1 million, or 64.7% of revenue, in the yea
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended March 31, 2024 after the market closes on Wednesday, May 8, 2024, and will host a conference call at 4:30 pm ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U.S. and Canada) or +1 (201) 689-8037 (International) and use conference ID number 13746251. The call will also be available via live or archived webcast on the "Investor Relations" section of the Establishment Labs website at www.establis
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the fourth quarter and full year ended December 31, 2023 and provided 2024 guidance. Fourth Quarter Highlights and Outlook 2024 revenue guidance of $174 million to $184 million, an increase of 5% to 11% over 2023. Guidance does not include revenue from Motiva Implants® in the United States, which is expected in 2024. Fourth quarter revenue of $31.6 million, consistent with preannouncement on January 9. Fourth quarter net loss from operations of $22.1 millio
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended December 31, 2023, after the market closes on Wednesday, February 28, 2024, and will host a conference call at 4:30 pm ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U.S. and Canada) or +1 (201) 689-8037 (International) and use conference ID number 13744589. The call will also be available via live or archived webcast on the "Investor Relations" section of the Establishment Labs website at ww
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the third quarter ended September 30, 2023. Third Quarter Highlights and Outlook Third quarter worldwide revenue of $38.5 million increased 0.8% year-over-year. 2023 revenue guidance updated to approximately $165 million, an increase of 2% over 2022. Third quarter loss from operations was $21.0 million compared to a loss of $10.5 million in the year-ago period. Cash balance of $52.2 million as of September 30, 2023. U.S. FDA clearance of the Motiva Fl
Flora is the only magnet-free and MR Conditional tissue expander cleared for the U.S. market. Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended Semptember 30, 2023, after the market closes on Tuesday, November 7, 2023, and will host a conference call at 4:30 pm ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U.S. and Canada) or (201) 689-8037 (International) and use conference ID number 13740398. The call will also be available via live or
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the second quarter ended June 30, 2023. First Quarter Highlights and Outlook Second quarter worldwide revenue of $48.6 million increased 18.0% year-over-year and was a new quarterly record. 2023 revenue guidance remains $200 million to $210 million, an increase of 24% to 30% over 2022. Second quarter loss from operations was $13.7 million compared to a loss of $10.4 million in the year-ago period as investment in growth initiatives increased. Cash balanc